Please login to the form below

Not currently logged in
Email:
Password:

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

SMCMultiple myeloma patients - who have received at least one prior therapy - in Scotland will soon be able to access Amgen’s Kyprolis (carfilzomib) in combination with dexamethasone via the NHS, following a recommendation by the Scottish Medicines Consortium (SMC).

This is a big milestone for the American biopharma group, as the drug is the first and only proteasome inhibitor to demonstrate improved overall survival.

Tony Patrikios, executive medical director at Amgen UK, said: “We know that time free of disease is precious and we are committed to advancing care for people with this difficult-to-treat blood cancer.

“We see carfilzomib as the backbone therapy for the management of relapsed multiple myeloma.”

The approval follows recommendation from the National Institute for Health and Care Excellence (NICE) coupled with positive results from the phase III randomised ENDEAVOR trial, which was the first head-to-head clinical study comparing two proteasome inhibitors.

The trial proved that patients treated with Amgen’s combination had a progression free survival (PFS) of 18.7 months while patients on Millennium’s Velcade (bortexomib) and dexamethasone only saw a PFS of 9.4 months.

Patrikios added: “We are pleased with the outcome from the Scottish Medicines Consortium and now patients in England, Wales and Scotland will have access to a treatment with proven evidence to prolong progression-free and overall survival.”

In the UK, it is estimated that there are approximately 17,500 people living with myeloma, accounting for around 2% of all cancers according to Myeloma UK.

Shelagh McKinlay, policy and public affairs officer for Myeloma UK, said: “The approval of carfilzomib and dexamethasone for use on the NHS gives myeloma patients, whose cancer come back, an important new treatment option.

“We are especially pleased that the approval covers all patients who have had one prior treatment as carfilzomib and dexamethasone has been shown to be very effective in prolonging survival in relapsed myeloma patients, and should be available to doctors as a prescribing option for their eligible patients.”

The NHS boards in Scotland now have a maximum of 60 days to include carfilzomib in its formularies providing Amgen UK complies with the terms of the agreed patient access scheme.

Continuing with the cancer field, AbbVie’s Venclyxto (venetoclax) also won SMC approval for the treatment of chronic lymphocytic leukaemia (CLL) in adult patients.

Ferring Pharmaceutical’s idiopathic nocturnal polyuria drug Noqdirna (desmopressin oral lypohilisate) also received a green light, however Biofrontera’s Ameluz (aminolaevulinic acid hydrochloride) wasn’t as lucky as the committee said the product was not cost-effective enough to give a recommendation.

Article by
Gemma Jones

9th August 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...